Takayuki Chikata
Lecturer
Research Interests
Explore related searches
Contact this professor
About
Takayuki Chikata is a Lecturer at Kumamoto University in Japan. His research primarily focuses on the immunological aspects of HIV-1 infection and disease progression, including the role of specific CD8 + T cells and HLA alleles. He has also contributed to studies on the diagnosis of Entamoeba histolytica and memory responses to SARS-CoV-2. His recent publications reflect a deep engagement with the mechanisms of viral evolution and immune response.
Articles (15)
Epitope-dependent effect of long-term cART on maintenance and recovery of HIV-1-specific CD8 <sup>+</sup> T cells
The frequency of HIV-1-specific T cells is reduced and their functional ability remains impaired in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). However, no studies have yet reported on T-cell responses to large numbers of well-characterized HIV-1 epitopes before and under cART within the same individuals. Therefore, how cART affects the maintenance of HIV-1-specific CD8 + T cells and which HIV-1-specific CD8 + T cells would be useful for curative treatment remain unclear. We investigated T-cell responses to 63 HIV-1 epitopes at pre-cART and under cART in 90 PLWH who received long-term cART. The frequency of T-cell responses to HIV-1 epitopes under long-term cART varied from 0% to 100%, indicating an epitope-dependent effect of long-term cART on HIV-1-specific CD8 + T cells. The magnitude of the responses under cART was 26.2% of that at pre-cART. The frequency of T-cell responses to protective epitopes under cART was higher than that to non-protective ones. T-cell responses to HIV-1 epitopes were detected at pre-cART in most non-AIDS HIV patients, whereas they were not detectable at pre-cART in half of the AIDS patients. Long-term cART enhanced the ability of HIV-1-specific T cells to proliferate in vitro in non-AIDS HIV patients, while it restored this ability of the T cells in AIDS patients. This study demonstrated that CD8 + T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and implied that some HIV-1-specific T cells are still candidates as effector cells for curative treatment. IMPORTANCE HIV-1-specific CD8 + T cells are anticipated to become effector cells for curative treatment using the “shock and kill” approach in people living with HIV-1 (PLWH) under combined antiretroviral therapy (cART). Previous studies demonstrated that the frequency of HIV-1-specific CD8 + T cells is reduced under cART and their functional ability remains impaired. These studies analyzed T-cell responses to a small number of HIV-1 epitopes or overlapping HIV-1 peptides. Therefore, the features of CD8 + T cells specific for HIV-1 epitopes under cART remain only partially clarified. Here, we analyzed CD8 + T cells specific for 63 well-characterized epitopes in 90 PLWH. We demonstrated that CD8 + T cells specific for large numbers of HIV-1 epitopes were maintained in an epitope-dependent fashion under long-term cART and that long-term cART enhanced or restored the ability of HIV-1-specific T cells to proliferate in vitro . This study implies that some HIV-1-specific T cells would be useful as effector cells for curative treatment.
Year:
2023
Collaborators (9)
Nicola Ternette
Professor
University of Dundee
Hirofumi Aso
Specially Appointed Assistant Professor
Tokyo Medical and Dental University
Mahoko Ueda
Assistant Professor
Tokyo Medical and Dental University
Eiji Morita
Hirosaki University
Chanson Brumme
Assistant Professor (Partner)
University of British Columbia Faculty of Medicine
Zabrina Brumme
Associate Professor
Simon Fraser University
Yoshifumi Nishimura
Yokohama National University
Masafumi Takiguchi
Kumamoto University
So Nakagawa
Associate Professor
Tokai University School of Medicine

How do I reach out?
Sign in for free to see their profile details and contact information.